Show simple item record

dc.contributor.authorMoore, Carmelen
dc.contributor.authorSambrook, Jenniferen
dc.contributor.authorWalker, Matthewen
dc.contributor.authorTolkien, Zoeen
dc.contributor.authorKaptoge, Stephenen
dc.contributor.authorAllen, Daviden
dc.contributor.authorMehenny, Susanen
dc.contributor.authorMant, Jonathanen
dc.contributor.authorDi, Angelantonio Emanueleen
dc.contributor.authorThompson, Simonen
dc.contributor.authorOuwehand, Willemen
dc.contributor.authorRoberts, David Jen
dc.contributor.authorDanesh, Johnen
dc.date.accessioned2014-09-18T15:52:48Z
dc.date.available2014-09-18T15:52:48Z
dc.date.issued2014-09-17en
dc.identifier.citationTrials 2014, 15:363 doi:10.1186/1745-6215-15-363en
dc.identifier.issn1745-6215
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/245992
dc.description.abstractBackground Ageing populations may demand more blood transfusions, but the blood supply could be limited by difficulties in attracting and retaining a decreasing pool of younger donors. One approach to increase blood supply is to collect blood more frequently from existing donors. If more donations could be safely collected in this manner at marginal cost, then it would be of considerable benefit to blood services. National Health Service (NHS) Blood and Transplant in England currently allows men to donate up to every 12 weeks and women to donate up to every 16 weeks. In contrast, some other European countries allow donations as frequently as every 8 weeks for men and every 10 weeks for women. The primary aim of the INTERVAL trial is to determine whether donation intervals can be safely and acceptably decreased to optimise blood supply whilst maintaining the health of donors. Methods INTERVAL is a randomised trial of whole blood donors enrolled from all 25 static centres of NHS Blood and Transplant. Recruitment of about 50,000 male and female donors started in June 2012 and was completed in June 2014. Men have been randomly assigned to standard 12-week versus 10-week versus 8-week inter-donation intervals, while women have been assigned to standard 16-week versus 14-week versus 12-week inter-donation intervals. Sex-specific comparisons will be made by intention-to-treat analysis of outcomes assessed after two years of intervention. The primary outcome is the number of blood donations made. A key secondary outcome is donor quality of life, assessed using the Short Form Health Survey. Additional secondary endpoints include the number of 'deferrals' due to low haemoglobin (and other factors), iron status, cognitive function, physical activity, and donor attitudes. A comprehensive health economic analysis will be undertaken. Discussion The INTERVAL trial should yield novel information about the effect of inter-donation intervals on blood supply, acceptability, and donors' physical and mental well-being. The study will generate scientific evidence to help formulate blood collection policies in England and elsewhere.
dc.description.sponsorshipThe trial is funded by NHS Blood and Transplant. The trial’s coordinating centre at the Department of Public Health and Primary Care at the University of Cambridge has received core support from the UK Medical Research Council, British Heart Foundation, and the UK National Institute of Health Research (Cambridge Biomedical Research Centre). Investigators at the University of Oxford have been supported by Research and Development Programme of NHSBT, the NHSBT Howard Ostin Trust Fund, the UK National Institute of Health Research (Oxford Biomedical Research Centre) through the Programme Grant NIHR-RP-PG-0310-1004 and the Oxford Biomedical Research Centre.
dc.languageEnglishen
dc.language.isoenen
dc.publisherBioMed Central
dc.rightsAttribution 2.0 UK: England & Wales*
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/uk/*
dc.titleThe INTERVAL Trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trialen
dc.typeArticle
dc.description.versionThis is the published version of the article. It is published by BioMed Central in Trials here: http://www.trialsjournal.com/content/15/1/363.en
prism.publicationDate2014en
prism.publicationNameTrialsen
prism.volume15en
dc.rioxxterms.funderMRC
dc.rioxxterms.funderBHF
dc.rioxxterms.funderNIHR
dcterms.dateAccepted2014-08-28en
rioxxterms.versionofrecord10.1186/1745-6215-15-363en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2014-09-17en
dc.contributor.orcidKaptoge, Stephen [0000-0002-1155-4872]
dc.contributor.orcidMant, Jonathan [0000-0002-9531-0268]
dc.contributor.orcidThompson, Simon [0000-0002-5274-7814]
dc.contributor.orcidOuwehand, Willem [0000-0002-7744-1790]
dc.contributor.orcidDanesh, John [0000-0003-1158-6791]
dc.identifier.eissn1745-6215
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (MR/L003120/1)
pubs.funder-project-idBritish Heart Foundation (RG/08/014/24067)
pubs.funder-project-idMRC (MC_qA137933)
pubs.funder-project-idBritish Heart Foundation (RG/09/012/28096)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution 2.0 UK: England & Wales